PEN241220C340000
- 15.30
- 0.000.00%
Penumbra Newsroom
BTIG Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $270
Cautious Hold Recommendation Amid Uncertainty Following FDA Clearance of Penumbra's Element Vascular Access System
Penumbra's Prospective Growth Amidst Market Dynamics Justifies Hold Rating
Penumbra Is Maintained at Overweight by Piper Sandler
Penumbra Price Target Raised to $250.00/Share From $235.00 by Piper Sandler
Penumbra Analyst Ratings
Piper Sandler Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $250
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Announces Target Price $240
Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)
Penumbra (PEN) Receives a Buy From BTIG
Penumbra's Strong Q3 2024 Performance and Future Growth Prospects Justify Buy Rating by William Plovanic
A Quick Look at Today's Ratings for Penumbra(PEN.US), With a Forecast Between $232 to $248
A Quick Look at Today's Ratings for Penumbra(PEN.US), With a Forecast Between $232 to $248
Penumbra Is Maintained at Outperform by Baird
Baird Maintains Outperform on Penumbra, Raises Price Target to $248
Penumbra Analyst Ratings
Penumbra Analyst Ratings
Needham Maintains Penumbra(PEN.US) With Hold Rating
Penumbra's Thunderbolt Study Progress and Market Impact: Matson Maintains Hold Rating
Piper Sandler Maintains Penumbra(PEN.US) With Buy Rating, Raises Target Price to $225